- key: '0'
  level: 1
  section_number: ''
  section_title: Title Sheet
  text: '<usdm:section name="M11-title-page"/>'
- key: '1'
  level: 1
  section_number: '1'
  section_title: Protocol Summary
  text: ''
- key: '1.1'
  level: 2
  section_number: '1.1'
  section_title: Protocol Synopsis
  text: ''
- key: 1.1.1
  level: 3
  section_number: 1.1.1
  section_title: Primary and Secondary Objectives and Endpoints
  text: ''
- key: 1.1.2
  level: 3
  section_number: 1.1.2
  section_title: Overall Design
  text: ''
- key: '1.2'
  level: 2
  section_number: '1.2'
  section_title: Trial Schema
  text: ''
- key: '1.3'
  level: 2
  section_number: '1.3'
  section_title: Schedule of Activities
  text: ''
- key: '2'
  level: 1
  section_number: '2'
  section_title: Introduction
  text: ''
- key: '2.1'
  level: 2
  section_number: '2.1'
  section_title: Purpose of Trial
  text: ''
- key: '2.2'
  level: 2
  section_number: '2.2'
  section_title: Summary of Benefits and Risks
  text: ''
- key: 2.2.1
  level: 3
  section_number: 2.2.1
  section_title: Benefit Summary
  text: ''
- key: 2.2.2
  level: 3
  section_number: 2.2.2
  section_title: Risk Summary and Mitigation Strategy
  text: ''
- key: 2.2.3
  level: 3
  section_number: 2.2.3
  section_title: Overall Benefit:Risk Conclusion
  text: ''
- key: '3'
  level: 1
  section_number: '3'
  section_title: Trial Objectives, Endpoints and Estimands
  text: ''
- key: '3.1'
  level: 2
  section_number: '3.1'
  section_title: '{Primary/Secondary/Exploratory} Objective + Associated Endpoint
    {and Estimand}'
  text: ''
- key: 3.1.1
  level: 3
  section_number: 3.1.1
  section_title: '{Primary/Secondary/Exploratory} Estimand'
  text: ''
- key: '4'
  level: 1
  section_number: '4'
  section_title: Trial Design
  text: ''
- key: '4.1'
  level: 2
  section_number: '4.1'
  section_title: Description of Trial Design
  text: ''
- key: 4.1.1
  level: 3
  section_number: 4.1.1
  section_title: Stakeholder Input into Design
  text: ''
- key: '4.2'
  level: 2
  section_number: '4.2'
  section_title: Rationale for Trial Design
  text: ''
- key: 4.2.1
  level: 3
  section_number: 4.2.1
  section_title: Rationale for Intervention Model
  text: ''
- key: 4.2.2
  level: 3
  section_number: 4.2.2
  section_title: Rationale for Duration
  text: ''
- key: 4.2.3
  level: 3
  section_number: 4.2.3
  section_title: Rationale for Endpoints
  text: ''
- key: 4.2.4
  level: 3
  section_number: 4.2.4
  section_title: Rationale for Interim Analysis
  text: ''
- key: 4.2.5
  level: 3
  section_number: 4.2.5
  section_title: Rationale for Comparator
  text: ''
- key: 4.2.6
  level: 3
  section_number: 4.2.6
  section_title: Rationale for Adaptive or Novel Trial Design
  text: ''
- key: 4.2.7
  level: 3
  section_number: 4.2.7
  section_title: Rationale for Other Trial Design Aspects
  text: ''
- key: '4.3'
  level: 2
  section_number: '4.3'
  section_title: Trial Stopping Rules
  text: ''
- key: 4.3.1
  level: 3
  section_number: 4.3.1
  section_title: '{Temporary Trial Halt}'
  text: ''
- key: '4.4'
  level: 2
  section_number: '4.4'
  section_title: Start of Trial and End of Trial
  text: ''
- key: '4.5'
  level: 2
  section_number: '4.5'
  section_title: Access to Trial Intervention After End of Trial
  text: ''
- key: '5'
  level: 1
  section_number: '5'
  section_title: Trial Population
  text: ''
- key: '5.1'
  level: 2
  section_number: '5.1'
  section_title: Description of Trial Population and Rationale
  text: ''
- key: '5.2'
  level: 2
  section_number: '5.2'
  section_title: Inclusion Criteria
  text: ''
- key: '5.3'
  level: 2
  section_number: '5.3'
  section_title: Exclusion Criteria
  text: ''
- key: '5.4'
  level: 2
  section_number: '5.4'
  section_title: Contraception
  text: ''
- key: '5.5'
  level: 2
  section_number: '5.5'
  section_title: Lifestyle Restrictions
  text: ''
- key: 5.5.1
  level: 3
  section_number: 5.5.1
  section_title: Meals and Dietary Restrictions
  text: ''
- key: 5.5.2
  level: 3
  section_number: 5.5.2
  section_title: Caffeine, Alcohol, Tobacco, and Other Restrictions
  text: ''
- key: 5.5.3
  level: 3
  section_number: 5.5.3
  section_title: Physical Activity Restrictions
  text: ''
- key: 5.5.4
  level: 3
  section_number: 5.5.4
  section_title: Other Activity Restrictions
  text: ''
- key: '5.6'
  level: 2
  section_number: '5.6'
  section_title: Screen Failure and Rescreening
  text: ''
- key: '6'
  level: 1
  section_number: '6'
  section_title: Trial Intervention And Concomitant Therapy
  text: ''
- key: '6.1'
  level: 2
  section_number: '6.1'
  section_title: Description of Investigational Trial Intervention
  text: ''
- key: '6.2'
  level: 2
  section_number: '6.2'
  section_title: Rationale for Investigational Trial Intervention Dose and Regimen
  text: ''
- key: '6.3'
  level: 2
  section_number: '6.3'
  section_title: Investigational Trial Intervention Administration
  text: ''
- key: 6.3.1
  level: 3
  section_number: 6.3.1
  section_title: Investigational Trial Intervention Dose Modification
  text: ''
- key: '6.4'
  level: 2
  section_number: '6.4'
  section_title: Management of Investigational Trial Intervention Overdose
  text: ''
- key: '6.5'
  level: 2
  section_number: '6.5'
  section_title: Preparation, Storage, Handling and Accountability of Investigational
    Trial Intervention(s)
  text: ''
- key: 6.5.1
  level: 3
  section_number: 6.5.1
  section_title: Preparation of Investigational Trial Intervention(s)
  text: ''
- key: 6.5.2
  level: 3
  section_number: 6.5.2
  section_title: Storage and Handling of Investigational Trial Intervention
  text: ''
- key: 6.5.3
  level: 3
  section_number: 6.5.3
  section_title: Accountability of Investigational Trial Intervention
  text: ''
- key: '6.6'
  level: 2
  section_number: '6.6'
  section_title: Investigational Trial Intervention Assignment, Randomisation and
    Blinding
  text: ''
- key: 6.6.1
  level: 3
  section_number: 6.6.1
  section_title: Participant Assignment to Investigational Trial Intervention
  text: ''
- key: 6.6.2
  level: 3
  section_number: 6.6.2
  section_title: Randomisation
  text: ''
- key: 6.6.3
  level: 3
  section_number: 6.6.3
  section_title: '{Blinding}'
  text: ''
- key: 6.6.4
  level: 3
  section_number: 6.6.4
  section_title: '{Emergency Unblinding at the Site}'
  text: ''
- key: '6.7'
  level: 2
  section_number: '6.7'
  section_title: Investigational Trial Intervention Compliance
  text: ''
- key: '6.8'
  level: 2
  section_number: '6.8'
  section_title: Description of Non-Investigational Trial Intervention(s)
  text: ''
- key: 6.8.1
  level: 3
  section_number: 6.8.1
  section_title: '{Background Intervention}'
  text: ''
- key: 6.8.2
  level: 3
  section_number: 6.8.2
  section_title: '{Rescue Therapy}'
  text: ''
- key: 6.8.3
  level: 3
  section_number: 6.8.3
  section_title: '{Other Therapy}'
  text: ''
- key: '6.9'
  level: 2
  section_number: '6.9'
  section_title: Concomitant Therapy
  text: ''
- key: 6.9.1
  level: 3
  section_number: 6.9.1
  section_title: '{Prohibited Concomitant Therapy}'
  text: ''
- key: 6.9.2
  level: 3
  section_number: 6.9.2
  section_title: '{Permitted Concomitant Therapy}'
  text: ''
- key: '7'
  level: 1
  section_number: '7'
  section_title: Participant Discontinuation of Trial Intervention and Withdrawal
    From trial
  text: ''
- key: '7.1'
  level: 2
  section_number: '7.1'
  section_title: Discontinuation of Trial Intervention for Individual Participants
  text: ''
- key: 7.1.1
  level: 3
  section_number: 7.1.1
  section_title: Permanent Discontinuation of Trial Intervention
  text: ''
- key: 7.1.2
  level: 3
  section_number: 7.1.2
  section_title: Temporary Discontinuation of Trial Intervention
  text: ''
- key: 7.1.3
  level: 3
  section_number: 7.1.3
  section_title: Rechallenge
  text: ''
- key: '7.2'
  level: 2
  section_number: '7.2'
  section_title: Withdrawal from the Trial
  text: ''
- key: '7.3'
  level: 2
  section_number: '7.3'
  section_title: Lost to Follow-Up
  text: ''
- key: '7.4'
  level: 2
  section_number: '7.4'
  section_title: Participant Stopping Rules
  text: ''
- key: '8'
  level: 1
  section_number: '8'
  section_title: Trial Assessments and Procedures
  text: ''
- key: '8.1'
  level: 2
  section_number: '8.1'
  section_title: Screening/Baseline Assessments and Procedures
  text: ''
- key: '8.2'
  level: 2
  section_number: '8.2'
  section_title: Efficacy Assessments and Procedures
  text: ''
- key: '8.3'
  level: 2
  section_number: '8.3'
  section_title: Safety Assessments and Procedures
  text: ''
- key: 8.3.1
  level: 3
  section_number: 8.3.1
  section_title: Physical Examination
  text: ''
- key: 8.3.2
  level: 3
  section_number: 8.3.2
  section_title: Vital Signs
  text: ''
- key: 8.3.3
  level: 3
  section_number: 8.3.3
  section_title: Electrocardiograms
  text: ''
- key: 8.3.4
  level: 3
  section_number: 8.3.4
  section_title: Clinical Laboratory Assessments
  text: ''
- key: 8.3.5
  level: 3
  section_number: 8.3.5
  section_title: Pregnancy Testing
  text: ''
- key: 8.3.6
  level: 3
  section_number: 8.3.6
  section_title: Suicidal Ideation and Behaviour Risk Monitoring
  text: ''
- key: '8.4'
  level: 2
  section_number: '8.4'
  section_title: Pharmacokinetics
  text: ''
- key: '8.5'
  level: 2
  section_number: '8.5'
  section_title: Genetic Testing
  text: ''
- key: '8.6'
  level: 2
  section_number: '8.6'
  section_title: Biomarkers
  text: ''
- key: '8.7'
  level: 2
  section_number: '8.7'
  section_title: Immunogenicity Assessments
  text: ''
- key: '8.8'
  level: 2
  section_number: '8.8'
  section_title: Medical Resource Utilisation and Health Economics
  text: ''
- key: '9'
  level: 1
  section_number: '9'
  section_title: Adverse Events, Serious Adverse Events, Product Complaints, Pregnancy
    and Postpartum Information
  text: ''
- key: '9.1'
  level: 2
  section_number: '9.1'
  section_title: Definitions
  text: ''
- key: 9.1.1
  level: 3
  section_number: 9.1.1
  section_title: Definitions of Adverse Events
  text: ''
- key: 9.1.2
  level: 3
  section_number: 9.1.2
  section_title: Definitions of Serious Adverse Events
  text: ''
- key: 9.1.3
  level: 3
  section_number: 9.1.3
  section_title: Definitions Related to Childbearing Potential
  text: ''
- key: 9.1.4
  level: 3
  section_number: 9.1.4
  section_title: '{Definition of Medical Device Product Complaints}'
  text: ''
- key: '9.2'
  level: 2
  section_number: '9.2'
  section_title: Timing and Mechanism for Collection and Reporting
  text: ''
- key: '9.3'
  level: 2
  section_number: '9.3'
  section_title: Identification, Recording and Follow-Up
  text: ''
- key: 9.3.1
  level: 3
  section_number: 9.3.1
  section_title: Identification
  text: ''
- key: 9.3.2
  level: 3
  section_number: 9.3.2
  section_title: Intensity
  text: ''
- key: 9.3.3
  level: 3
  section_number: 9.3.3
  section_title: Causality
  text: ''
- key: 9.3.4
  level: 3
  section_number: 9.3.4
  section_title: Follow-up
  text: ''
- key: '9.4'
  level: 2
  section_number: '9.4'
  section_title: Reporting
  text: ''
- key: 9.4.1
  level: 3
  section_number: 9.4.1
  section_title: Regulatory Reporting Requirements
  text: ''
- key: 9.4.2
  level: 3
  section_number: 9.4.2
  section_title: Adverse Events of Special Interest
  text: ''
- key: 9.4.3
  level: 3
  section_number: 9.4.3
  section_title: Disease-related Events or Outcomes Not Qualifying as AEs or SAEs
  text: ''
- key: '9.5'
  level: 2
  section_number: '9.5'
  section_title: Pregnancy and Postpartum Information
  text: ''
- key: 9.5.1
  level: 3
  section_number: 9.5.1
  section_title: '{Participants Who Become Pregnant During the Trial}'
  text: ''
- key: 9.5.2
  level: 3
  section_number: 9.5.2
  section_title: '{Participants Whose Partners Become Pregnant}'
  text: ''
- key: '10'
  level: 1
  section_number: '10'
  section_title: Statistical Considerations
  text: ''
- key: '10.1'
  level: 2
  section_number: '10.1'
  section_title: Analysis Sets
  text: ''
- key: '10.2'
  level: 2
  section_number: '10.2'
  section_title: Analyses Supporting Primary Objective(s)
  text: ''
- key: 10.2.1
  level: 3
  section_number: 10.2.1
  section_title: Statistical Model, Hypothesis, and Method of Analysis
  text: ''
- key: 10.2.2
  level: 3
  section_number: 10.2.2
  section_title: Handling of Intercurrent Events of Primary Estimand(s)
  text: ''
- key: 10.2.3
  level: 3
  section_number: 10.2.3
  section_title: Handling of Missing Data
  text: ''
- key: 10.2.4
  level: 3
  section_number: 10.2.4
  section_title: Sensitivity Analysis
  text: ''
- key: 10.2.5
  level: 3
  section_number: 10.2.5
  section_title: Supplementary Analysis
  text: ''
- key: '10.3'
  level: 2
  section_number: '10.3'
  section_title: Analysis Supporting Secondary Objective(s)
  text: ''
- key: '10.4'
  level: 2
  section_number: '10.4'
  section_title: Analysis of Exploratory Objective(s)
  text: ''
- key: '10.5'
  level: 2
  section_number: '10.5'
  section_title: Safety Analyses
  text: ''
- key: '10.6'
  level: 2
  section_number: '10.6'
  section_title: Other Analyses
  text: ''
- key: '10.7'
  level: 2
  section_number: '10.7'
  section_title: Interim Analyses
  text: ''
- key: '10.8'
  level: 2
  section_number: '10.8'
  section_title: Sample Size Determination
  text: ''
- key: '10.9'
  level: 2
  section_number: '10.9'
  section_title: Protocol Deviations
  text: ''
- key: '11'
  level: 1
  section_number: '11'
  section_title: 'General Considerations: Regulatory, Ethical, And trial Oversight'
  text: ''
- key: '11.1'
  level: 2
  section_number: '11.1'
  section_title: Regulatory and Ethical Considerations
  text: ''
- key: '11.2'
  level: 2
  section_number: '11.2'
  section_title: Trial Oversight
  text: ''
- key: 11.2.1
  level: 3
  section_number: 11.2.1
  section_title: Investigator Responsibilities
  text: ''
- key: 11.2.2
  level: 3
  section_number: 11.2.2
  section_title: Sponsor Responsibilities
  text: ''
- key: '11.3'
  level: 2
  section_number: '11.3'
  section_title: Committees
  text: ''
- key: '11.4'
  level: 2
  section_number: '11.4'
  section_title: Informed Consent Process
  text: ''
- key: 11.4.1
  level: 3
  section_number: 11.4.1
  section_title: Informed Consent for Rescreening
  text: ''
- key: 11.4.2
  level: 3
  section_number: 11.4.2
  section_title: Informed Consent for Use of Remaining Samples in Exploratory Research
  text: ''
- key: '11.5'
  level: 2
  section_number: '11.5'
  section_title: Insurance and Indemnity
  text: ''
- key: '11.6'
  level: 2
  section_number: '11.6'
  section_title: Early Site Closure
  text: ''
- key: '12'
  level: 1
  section_number: '12'
  section_title: 'General Considerations: Risk Management and Data Governance'
  text: ''
- key: '12.1'
  level: 2
  section_number: '12.1'
  section_title: Risk Management
  text: ''
- key: '12.2'
  level: 2
  section_number: '12.2'
  section_title: Data Governance
  text: ''
- key: '12.3'
  level: 2
  section_number: '12.3'
  section_title: Source Data
  text: ''
- key: '13'
  level: 1
  section_number: '13'
  section_title: 'Appendix: Definitions and Supporting Operational Details'
  text: ''
- key: '13.1'
  level: 2
  section_number: '13.1'
  section_title: Clinical Laboratory Tests
  text: ''
- key: '13.2'
  level: 2
  section_number: '13.2'
  section_title: Country/Region-Specific Differences
  text: ''
- key: '13.3'
  level: 2
  section_number: '13.3'
  section_title: Prior Protocol Amendment(s)
  text: ''
- key: '14'
  level: 1
  section_number: '14'
  section_title: 'Appendix:  Glossary of Terms and Abbreviations'
  text: ''
- key: '15'
  level: 1
  section_number: '15'
  section_title: 'Appendix:  References'
  text: ''
